# Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

> **NCT01369095** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 976 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Duloxetine
- **DRUG:** Escitalopram
- **DRUG:** BMS-820836 Placebo
- **DRUG:** BMS-820836
- **DRUG:** BMS-820836
- **DRUG:** BMS-820836
- **DRUG:** BMS-820836

## Key facts

- **NCT ID:** NCT01369095
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 976 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01369095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01369095, "Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01369095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*